Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma

被引:42
作者
Messiou, Christina [1 ,2 ]
Porta, Nuria [2 ]
Sharma, Bhupinder [1 ]
Levine, Daniel [1 ]
Koh, Dow-Mu [1 ,2 ]
Boyd, Kevin [1 ]
Pawlyn, Charlotte [1 ,2 ]
Riddell, Angela [1 ]
Downey, Katherine [1 ]
Croft, James [1 ]
Morgan, Veronica [1 ]
Stern, Simon [1 ,3 ]
Cheung, Betty [4 ]
Kyriakou, Charalampia [5 ]
Kaczmarek, Pawel [6 ]
Winfield, Jessica [1 ,2 ]
Blackledge, Matthew [2 ]
Oyen, Wim J. G. [1 ,2 ]
Kaiser, Martin F. [1 ,2 ]
机构
[1] Royal Marsden Hosp Fdn NHS Tust, Fulham Rd, London SW3 6JJ, England
[2] Inst Canc Res, London, England
[3] Epsom & St Helier Univ Hosp NHS Trust, Epsom, Surrey, England
[4] Croydon Univ Hosp, Croydon, England
[5] Univ Coll London Hosp NHS Fdn Trust, London, England
[6] Surrey & Sussex Healthcare NHS Trust, Redhill, Surrey, England
来源
RADIOLOGY-IMAGING CANCER | 2021年 / 3卷 / 05期
基金
英国医学研究理事会; 英国工程与自然科学研究理事会;
关键词
MR-Imaging; Skeletal-Appendicular; Skeletal-Axial; Bone Marrow; Hematologic Diseases; Oncology; POSITRON-EMISSION-TOMOGRAPHY; HIGH-RISK CYTOGENETICS; MULTIPLE-MYELOMA; PROGNOSTIC-SIGNIFICANCE; BONE-MARROW; SYMPTOMATIC PATIENTS; COMPUTED-TOMOGRAPHY; IMAGING TECHNIQUES; F-18-FDG PET/CT; CONSENSUS;
D O I
10.1148/rycan.2021210048
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To compare disease detection of myeloma using contemporary whole-body (WB) MRI and fluorine 18 (F-18) fluorodeoxyglucose (FDG) PET/CT protocols and to correlate imaging with laboratory estimates of disease burden, including molecular characteristics. Materials and Methods: In this observational, prospective study, participants were recruited from November 2015 to March 2018 who had a diagnosis of myeloma, who were planned to undergo chemotherapy and autologous stem cell transplantation, and who underwent baseline WB-MRI and FDG PET/CT (ClinicalTrials.gov identifier NCT02403102). Baseline clinical data, including genetics, were collected. Paired methods were used to compare burden and patterns of disease. Results: Sixty participants (mean age, 60 years +/- 9 [standard deviation]; 35 men) underwent baseline WB-MRI and FDG PET/CT. WB-MRI showed significantly higher detection for focal lesions at all anatomic sites (except ribs, scapulae, and clavicles) and for diffuse disease at all sites. Two participants presented with two or more focal lesions smaller than 5 mm only at WB-MRI but not FDG PET/CT. Participants with diffuse disease at MRI had higher plasma cell infiltration (percentage of nucleated cells: median, 60% [interquartile range {IQR}, 50%-61%] vs 15% [IQR, 4%-50%]; P =.03) and paraprotein levels (median, 32.0 g/L [IQR, 24.0-48.0 g/L] vs 20.0 g/L [IQR, 12.0-22.6 g/L]; P =.02) compared with those without diffuse disease. All genetically high-risk tumors showed diffuse infiltration at WB-MRI. Conclusion: WB-MRI helped detect a higher number of myeloma lesions than FDG PET/CT, and diffuse disease detected at WB-MRI correlated with laboratory measures of disease burden and molecular markers of risk.
引用
收藏
页数:15
相关论文
共 43 条
[31]   Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: A single center experience on 228 patients [J].
Moulopoulos, Lia A. ;
Dimopoulos, Meletios A. ;
Kastritis, Efstathios ;
Christoulas, Dimitrios ;
Gkotzamanidou, Maria ;
Roussou, Maria ;
Koureas, Andreas ;
Migkou, Magdalini ;
Gavriatopoulou, Maria ;
Eleutherakis-Papaiakovou, Evangelos ;
Gika, Dimitra ;
Koutoulidis, Vasilios ;
Terpos, Evangelos .
AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (09) :861-864
[32]   Report of the 6th International Workshop on PET in lymphoma [J].
Nanni, Cristina ;
Cottereau, Anne Segolene ;
Lopci, Egesta ;
Bodet-Milin, Caroline ;
Coronado, Monica ;
Pro, Barbara ;
Kim, Wong Seog ;
Trotman, Judith ;
Barrington, Sally ;
Duhrsen, Ulrich ;
Vander Borght, Thierry ;
Zamagni, Elena ;
Kraeber-Bodere, Francoise ;
Messiou, Christina ;
Rahmouni, Alain ;
Buvat, Irene ;
Andre, Marc ;
Hertzberg, Mark ;
Oyen, Wim ;
Casasnovas, Olivier ;
Luminari, Stefano ;
Garderet, Laurent ;
Montravers, Francoise ;
Kobe, Carsten ;
Kluge, Regine ;
Versari, Annibale ;
Zucca, Emanuele ;
Moreau, Philippe ;
Cheson, Bruce ;
Haioun, Corinne ;
Gallamini, Andrea ;
Meignan, Michel .
LEUKEMIA & LYMPHOMA, 2017, 58 (10) :2298-2303
[33]   Chemokine receptor-4 targeted PET/CT with 68Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to 18F-FDG PET/CT [J].
Pan, Qingqing ;
Cao, Xinxin ;
Luo, Yaping ;
Li, Jian ;
Feng, Jun ;
Li, Fan .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (03) :537-546
[34]   Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma? [J].
Pawlyn, C. ;
Fowkes, L. ;
Otero, S. ;
Jones, J. R. ;
Boyd, K. D. ;
Davies, F. E. ;
Morgan, G. J. ;
Collins, D. J. ;
Sharma, B. ;
Riddell, A. ;
Kaiser, M. F. ;
Messiou, C. .
LEUKEMIA, 2016, 30 (06) :1446-1448
[35]   International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma [J].
Rajkumar, S. Vincent ;
Dimopoulos, Meletios A. ;
Palumbo, Antonio ;
Blade, Joan ;
Merlini, Giampaolo ;
Mateos, Maria-Victoria ;
Kumar, Shaji ;
Hillengass, Jens ;
Kastritis, Efstathios ;
Richardson, Paul ;
Landgren, Ola ;
Paiva, Bruno ;
Dispenzieri, Angela ;
Weiss, Brendan ;
Leleu, Xavier ;
Zweegman, Sonja ;
Lonial, Sagar ;
Rosinol, Laura ;
Zamagni, Elena ;
Jagannath, Sundar ;
Sezer, Orhan ;
Kristinsson, Sigurdur Y. ;
Caers, Jo ;
Usmani, Saad Z. ;
Lahuerta, Juan Jose ;
Johnsen, Hans Erik ;
Beksac, Meral ;
Cavo, Michele ;
Goldschmidt, Hartmut ;
Terpos, Evangelos ;
Kyle, Robert A. ;
Anderson, Kenneth C. ;
Durie, Brian G. M. ;
San Miguel, Jesus F. .
LANCET ONCOLOGY, 2014, 15 (12) :E538-E548
[36]   Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing [J].
Rasche, L. ;
Chavan, S. S. ;
Stephens, O. W. ;
Patel, P. H. ;
Tytarenko, R. ;
Ashby, C. ;
Bauer, M. ;
Stein, C. ;
Deshpande, S. ;
Wardell, C. ;
Buzder, T. ;
Molnar, G. ;
Zangari, M. ;
van Rhee, F. ;
Thanendrarajan, S. ;
Schinke, C. ;
Epstein, J. ;
Davies, F. E. ;
Walker, B. A. ;
Meissner, T. ;
Barlogie, B. ;
Morgan, G. J. ;
Weinhold, N. .
NATURE COMMUNICATIONS, 2017, 8
[37]   Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma [J].
Rasche, Leo ;
Angtuaco, Edgardo ;
McDonald, James E. ;
Buros, Amy ;
Stein, Caleb ;
Pawlyn, Charlotte ;
Thanendrarajan, Sharmilan ;
Schinke, Carolina ;
Samant, Rohan ;
Yaccoby, Shmuel ;
Walker, Brian A. ;
Epstein, Joshua ;
Zangari, Maurizio ;
van Rhee, Frits ;
Meissner, Tobias ;
Goldschmidt, Hartmut ;
Hemminki, Kari ;
Houlston, Richard ;
Barlogie, Bart ;
Davies, Faith E. ;
Morgan, Gareth J. ;
Weinhold, Niels .
BLOOD, 2017, 130 (01) :30-34
[38]  
Sachpekidis C, 2015, AM J NUCL MED MOLEC, V5, P479
[39]   Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group [J].
Sonneveld, Pieter ;
Avet-Loiseau, Herve ;
Lonial, Sagar ;
Usmani, Saad ;
Siegel, David ;
Anderson, Kenneth C. ;
Chng, Wee-Joo ;
Moreau, Philippe ;
Attal, Michel ;
Kyle, Robert A. ;
Caers, Jo ;
Hillengass, Jens ;
San Miguel, Jesus ;
van de Donk, Niels W. C. J. ;
Einsele, Hermann ;
Blade, Joan ;
Durie, Brian G. M. ;
Goldschmidt, Hartmut ;
Mateos, Maria-Victoria ;
Palumbo, Antonio ;
Orlowski, Robert .
BLOOD, 2016, 127 (24) :2955-2962
[40]   CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging [J].
Ulaner, Gary A. ;
Sobol, Nicholas B. ;
O'Donoghue, Joseph A. ;
Kirov, Assen S. ;
Riedl, Christopher C. ;
Min, Ryan ;
Smith, Eric ;
Carter, Lukas M. ;
Lyashchenko, Serge K. ;
Lewis, Jason S. ;
Landgren, C. Ola .
RADIOLOGY, 2020, 295 (03) :606-615